{"transactions":[{"id":729141,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T21:45:03.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":3127,"derivative":{"exercise_price":162.99,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":3127},"source":{"system":"sec-edgar","filing":"0001610717-26-000286","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071726000286/form4.xml","form_type":"4"}},{"id":729140,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-23T21:45:03.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":1191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 6,083 restricted stock units."}],"balance_after":97765,"source":{"system":"sec-edgar","filing":"0001610717-26-000286","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071726000286/form4.xml","form_type":"4"}},{"id":729130,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:24:48.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001638709-26-000004","document":"form4-06232026_090644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000163870926000004/form4-06232026_090644.xml","form_type":"4"}},{"id":786810,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-08T21:04:05.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":2092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."}],"balance_after":2092,"derivative":{"underlying":"Common Stock","underlying_shares":2092},"source":{"system":"sec-edgar","filing":"0001682852-26-000093","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000093/form4.xml","form_type":"4"}},{"id":786809,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T21:04:05.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":9681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."}],"balance_after":9681,"derivative":{"exercise_price":48.79,"expiration_date":"2036-05-06","underlying":"Common Stock","underlying_shares":9681},"source":{"system":"sec-edgar","filing":"0001682852-26-000093","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000093/form4.xml","form_type":"4"}},{"id":793851,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T21:39:26.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":16233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 30, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 30, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16233},"source":{"system":"sec-edgar","filing":"0001682852-26-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000075/form4.xml","form_type":"4"}},{"id":793850,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-04T21:39:26.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":16233,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":18585,"source":{"system":"sec-edgar","filing":"0001682852-26-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000075/form4.xml","form_type":"4"}},{"id":310093,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2026-05-04T20:31:49.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":4884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026."}],"balance_after":4884,"derivative":{"exercise_price":130.84,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":4884},"source":{"system":"sec-edgar","filing":"0001638709-26-000002","document":"wk-form4_1777926706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000163870926000002/wk-form4_1777926706.xml","form_type":"4"}},{"id":310092,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:31:49.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":1146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 1,146 restricted stock units (\"RSUs\") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026."}],"balance_after":6293,"source":{"system":"sec-edgar","filing":"0001638709-26-000002","document":"wk-form4_1777926706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000163870926000002/wk-form4_1777926706.xml","form_type":"4"}},{"id":1099232,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-30T20:27:49.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":11574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":11574,"derivative":{"exercise_price":37.48,"expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":11574},"source":{"system":"sec-edgar","filing":"0001610717-25-000273","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071725000273/form4.xml","form_type":"4"}},{"id":1099231,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-30T20:27:49.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":3142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 8,392 Restricted Stock Units."}],"balance_after":96574,"source":{"system":"sec-edgar","filing":"0001610717-25-000273","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071725000273/form4.xml","form_type":"4"}},{"id":1111598,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:27.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017238","document":"form4-06132025_050624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000141588925017238/form4-06132025_050624.xml","form_type":"4"}},{"id":322386,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2025-05-09T00:26:11.000Z","date":"2025-05-07","kind":"grant","planned":false,"acquired":true,"shares":6809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option vested immediately upon the grant date of May 7, 2025."}],"balance_after":6809,"derivative":{"exercise_price":98.9,"expiration_date":"2035-05-07","underlying":"Common Stock","underlying_shares":6809},"source":{"system":"sec-edgar","filing":"0001127602-25-013774","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760225013774/form4.xml","form_type":"4"}},{"id":322385,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-09T00:26:11.000Z","date":"2025-05-07","kind":"grant","planned":false,"acquired":true,"shares":1516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 1,516 restricted stock units (\"RSUs\") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 7, 2025."}],"balance_after":5147,"source":{"system":"sec-edgar","filing":"0001127602-25-013774","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760225013774/form4.xml","form_type":"4"}},{"id":1162455,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-01T20:28:12.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":16233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."}],"balance_after":16233,"derivative":{"underlying":"Common Stock","underlying_shares":16233},"source":{"system":"sec-edgar","filing":"0001127602-25-012934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760225012934/form4.xml","form_type":"4"}},{"id":1162454,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-01T20:28:12.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 30, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 30, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":979},"source":{"system":"sec-edgar","filing":"0001127602-25-012934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760225012934/form4.xml","form_type":"4"}},{"id":1162453,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-01T20:28:12.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":2352,"source":{"system":"sec-edgar","filing":"0001127602-25-012934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760225012934/form4.xml","form_type":"4"}},{"id":1467180,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T21:05:38.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":10248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Stock Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date."}],"balance_after":10248,"derivative":{"exercise_price":37.54,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":10248},"source":{"system":"sec-edgar","filing":"0001610717-24-000373","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071724000373/form4.xml","form_type":"4/A","original_submission_date":"2024-06-24"}},{"id":1467179,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-28T21:05:38.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":2945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 11,695 restricted stock units (\"RSUs\")."}],"balance_after":93432,"source":{"system":"sec-edgar","filing":"0001610717-24-000373","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071724000373/form4.xml","form_type":"4/A","original_submission_date":"2024-06-24"}},{"id":1470662,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T20:23:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":16700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":16700,"derivative":{"exercise_price":37.54,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":16700},"source":{"system":"sec-edgar","filing":"0001610717-24-000362","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071724000362/form4.xml","form_type":"4"}},{"id":1470661,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-24T20:23:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 13,550 Restricted Stock Units."}],"balance_after":95287,"source":{"system":"sec-edgar","filing":"0001610717-24-000362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071724000362/form4.xml","form_type":"4"}},{"id":1475256,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T21:00:25.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":23000,"derivative":{"exercise_price":12.36,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-24-017444","document":"form4-06182024_050611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000141588924017444/form4-06182024_050611.xml","form_type":"4"}},{"id":333999,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2024-05-09T19:46:28.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":12648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024."}],"balance_after":12648,"derivative":{"exercise_price":64.92,"expiration_date":"2034-05-08","underlying":"Common Stock","underlying_shares":12648},"source":{"system":"sec-edgar","filing":"0001127602-24-014767","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760224014767/form4.xml","form_type":"4"}},{"id":333998,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2024-05-09T19:46:28.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":2310,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the restricted stock units vested immediately upon the grant date of May 8, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the restricted stock units vested immediately upon the grant date of May 8, 2024."}],"balance_after":7801,"derivative":{"underlying":"Common Stock","underlying_shares":2310},"source":{"system":"sec-edgar","filing":"0001127602-24-014767","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760224014767/form4.xml","form_type":"4"}},{"id":1524792,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-05-07T20:54:53.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":979,"derivative":{"underlying":"Common Stock","underlying_shares":979},"source":{"system":"sec-edgar","filing":"0001127602-24-014466","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760224014466/form4.xml","form_type":"4"}},{"id":1524791,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-07T20:54:53.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":5668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":5668,"derivative":{"exercise_price":122.13,"expiration_date":"2034-05-06","underlying":"Common Stock","underlying_shares":5668},"source":{"system":"sec-edgar","filing":"0001127602-24-014466","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760224014466/form4.xml","form_type":"4"}},{"id":1742234,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-15T01:15:18.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":36800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of November 8, 2023, subject to the reporting person's continued employment or service relationship with the Company on each such vesting date."}],"balance_after":36800,"derivative":{"exercise_price":20.02,"expiration_date":"2033-11-08","underlying":"Common Stock","underlying_shares":36800},"source":{"system":"sec-edgar","filing":"0001610717-23-000356","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071723000356/form4.xml","form_type":"4"}},{"id":1742233,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Earn-out Shares","published_at":"2023-11-15T01:15:18.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":10651,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the \"Earn-out Shares\"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.  The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the \"Earn-out Shares\"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.  The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the \"Earn-out Shares\"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.  The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares."}],"balance_after":10651,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":10651},"source":{"system":"sec-edgar","filing":"0001610717-23-000356","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071723000356/form4.xml","form_type":"4"}},{"id":1742232,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-15T01:15:18.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 10,500 restricted stock units."}],"balance_after":90487,"source":{"system":"sec-edgar","filing":"0001610717-23-000356","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071723000356/form4.xml","form_type":"4"}},{"id":1742231,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-15T01:15:18.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":27696,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, a stock option to purchase shares of EQRx, Inc. common stock that was outstanding immediately prior to the Effective Time was cancelled and converted automatically into the right to receive 27,696 shares of the Company's common stock. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, a stock option to purchase shares of EQRx, Inc. common stock that was outstanding immediately prior to the Effective Time was cancelled and converted automatically into the right to receive 27,696 shares of the Company's common stock. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder."}],"balance_after":79987,"source":{"system":"sec-edgar","filing":"0001610717-23-000356","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071723000356/form4.xml","form_type":"4"}},{"id":1742230,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-15T01:15:18.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":52291,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the \"Merger Agreement\"), at the effective time of the first merger contemplated by the Merger Agreement (the \"Effective Time\"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the \"Company\"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the \"Merger Agreement\"), at the effective time of the first merger contemplated by the Merger Agreement (the \"Effective Time\"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the \"Company\"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder."}],"balance_after":52291,"source":{"system":"sec-edgar","filing":"0001610717-23-000356","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000161071723000356/form4.xml","form_type":"4"}},{"id":1745829,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Earn-out Shares","published_at":"2023-11-09T16:13:43.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":107929,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the \"DeSPAC Merger Agreement\"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the \"Earn-out Shares\"), (i) 75,550 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the \"DeSPAC Merger Agreement\"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the \"Earn-out Shares\"), (i) 75,550 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the \"Exchange Ratio\") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement."}],"balance_after":0,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":107929},"source":{"system":"sec-edgar","filing":"0000899243-23-020303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020303/doc4.xml","form_type":"4"}},{"id":1745828,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-09T16:13:43.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":101010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an \"In-the-Money Option\") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration)."}],"balance_after":0,"derivative":{"exercise_price":4.95,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":101010},"source":{"system":"sec-edgar","filing":"0000899243-23-020303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020303/doc4.xml","form_type":"4"}},{"id":1745827,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-09T16:13:43.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":313500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an \"In-the-Money Option\") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration)."}],"balance_after":0,"derivative":{"exercise_price":0.44,"expiration_date":"2030-08-21","underlying":"Common Stock","underlying_shares":313500},"source":{"system":"sec-edgar","filing":"0000899243-23-020303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020303/doc4.xml","form_type":"4"}},{"id":1745826,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T16:13:43.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":470250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the \"Exchange Ratio\") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-020303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020303/doc4.xml","form_type":"4"}},{"id":1847806,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:30.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":7.84,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-23-010105","document":"form4-06212023_050618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000141588923010105/form4-06212023_050618.xml","form_type":"4"}},{"id":1902781,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-05T20:11:28.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":6134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":6134,"derivative":{"exercise_price":130.14,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":6134},"source":{"system":"sec-edgar","filing":"0001127602-23-014677","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760223014677/form4.xml","form_type":"4"}},{"id":349448,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2023-05-04T22:02:37.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":10173,"price":79.45,"value":808244.85,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023."}],"balance_after":10173,"derivative":{"exercise_price":79.45,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":10173},"source":{"system":"sec-edgar","filing":"0001127602-23-014558","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760223014558/form4.xml","form_type":"4"}},{"id":349447,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-04T22:02:37.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":1887,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 1,887 restricted stock units (\"RSUs\") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023."}],"balance_after":3631,"source":{"system":"sec-edgar","filing":"0001127602-23-014558","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760223014558/form4.xml","form_type":"4"}},{"id":1910161,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-05-01T21:35:16.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":false,"shares":670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 28, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":670},"source":{"system":"sec-edgar","filing":"0001127602-23-013922","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760223013922/form4.xml","form_type":"4"}},{"id":1910160,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-01T21:35:16.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":true,"shares":670,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1373,"source":{"system":"sec-edgar","filing":"0001127602-23-013922","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760223013922/form4.xml","form_type":"4"}},{"id":2068406,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Earn-out Shares","published_at":"2023-01-04T21:55:48.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":565,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 395 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 395 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 395 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 395 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."}],"balance_after":107929,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":565},"source":{"system":"sec-edgar","filing":"0001104659-23-001114","document":"tm231679-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923001114/tm231679-10_4seq1.xml","form_type":"4"}},{"id":2144969,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-04T20:29:24.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":101010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan)."}],"balance_after":101010,"derivative":{"exercise_price":4.95,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":101010},"source":{"system":"sec-edgar","filing":"0001104659-22-106023","document":"tm2227449-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465922106023/tm2227449-6_4seq1.xml","form_type":"4"}},{"id":2221129,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T21:15:02.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"date","element":"transactionDate","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.61,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006964","document":"form4a-06272022_020650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000141588922006964/form4a-06272022_020650.xml","form_type":"4/A","original_submission_date":"2022-06-17"}},{"id":2227837,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T23:30:59.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.43,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006786","document":"form4-06172022_040650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000141588922006786/form4-06172022_040650.xml","form_type":"4"}},{"id":361739,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2022-05-06T22:29:55.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":15851,"price":61.35,"value":972458.85,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022."}],"balance_after":15851,"derivative":{"exercise_price":61.35,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":15851},"source":{"system":"sec-edgar","filing":"0001127602-22-013715","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760222013715/form4.xml","form_type":"4"}},{"id":361738,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2022-05-06T22:29:55.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":2444,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the restricted stock units vested immediately upon the grant date of May 5, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the restricted stock units vested immediately upon the grant date of May 5, 2022."}],"balance_after":5491,"derivative":{"underlying":"Common Stock","underlying_shares":2444},"source":{"system":"sec-edgar","filing":"0001127602-22-013715","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760222013715/form4.xml","form_type":"4"}},{"id":361946,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2022-05-04T00:15:38.000Z","date":"2022-05-03","kind":"exercise","acquired":false,"shares":1112,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the restricted stock units vested on May 3, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the restricted stock units vested on May 3, 2022."}],"balance_after":3047,"derivative":{"underlying":"Common Stock","underlying_shares":1112},"source":{"system":"sec-edgar","filing":"0001127602-22-013127","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760222013127/form4.xml","form_type":"4"}},{"id":361945,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-04T00:15:38.000Z","date":"2022-05-03","kind":"exercise","acquired":true,"shares":1112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."}],"balance_after":1744,"source":{"system":"sec-edgar","filing":"0001127602-22-013127","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760222013127/form4.xml","form_type":"4"}},{"id":2286503,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-05-02T20:38:59.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":670,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":670},"source":{"system":"sec-edgar","filing":"0001127602-22-012854","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222012854/form4.xml","form_type":"4"}},{"id":2286502,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-02T20:38:59.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":4061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":4061,"derivative":{"exercise_price":142.52,"underlying":"Common Stock","underlying_shares":4061},"source":{"system":"sec-edgar","filing":"0001127602-22-012854","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222012854/form4.xml","form_type":"4"}},{"id":2286501,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-05-02T20:38:59.000Z","date":"2022-04-28","kind":"exercise","acquired":false,"shares":703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 28, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 28, 2022."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":703},"source":{"system":"sec-edgar","filing":"0001127602-22-012854","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222012854/form4.xml","form_type":"4"}},{"id":2286500,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-02T20:38:59.000Z","date":"2022-04-28","kind":"exercise","acquired":true,"shares":703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":703,"source":{"system":"sec-edgar","filing":"0001127602-22-012854","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222012854/form4.xml","form_type":"4"}},{"id":2462637,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Earn-out Shares","published_at":"2021-12-21T06:30:34.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":107364,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 75,155 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 75,155 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 75,155 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 75,155 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."}],"balance_after":107364,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":107364},"source":{"system":"sec-edgar","filing":"0000899243-21-049126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049126/doc4.xml","form_type":"4"}},{"id":2462636,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-21T06:30:34.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":313500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the \"2019 Plan\") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock.  The shares underlying this option vest and become exercisable in 16 equal quarterly installments commencing August 21, 2020, subject to the  Reporting Person's continuous service as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the \"2019 Plan\") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock.  The shares underlying this option vest and become exercisable in 16 equal quarterly installments commencing August 21, 2020, subject to the  Reporting Person's continuous service as of each vesting date."}],"balance_after":313500,"derivative":{"exercise_price":0.44,"expiration_date":"2030-08-21","underlying":"Common Stock","underlying_shares":313500},"source":{"system":"sec-edgar","filing":"0000899243-21-049126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049126/doc4.xml","form_type":"4"}},{"id":2462635,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T06:30:34.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":470250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 17, 2021, upon consummation of  the transactions (the \"Closing\" of the \"Business Combination\") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the \"Merger Agreement\") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., \"Legacy EQRx\"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 17, 2021, upon consummation of  the transactions (the \"Closing\" of the \"Business Combination\") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the \"Merger Agreement\") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., \"Legacy EQRx\"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock."}],"balance_after":470250,"source":{"system":"sec-edgar","filing":"0000899243-21-049126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049126/doc4.xml","form_type":"4"}},{"id":2673958,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-10T22:39:20.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":27.66,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-21-002927","document":"form4-06102021_030608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000141588921002927/form4-06102021_030608.xml","form_type":"4"}},{"id":375565,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2021-05-14T20:15:08.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":14665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting."}],"balance_after":14665,"derivative":{"exercise_price":67.45,"expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":14665},"source":{"system":"sec-edgar","filing":"0001127602-21-016827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760221016827/form4.xml","form_type":"4"}},{"id":375564,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2021-05-14T20:15:08.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":2223,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting."}],"balance_after":4159,"derivative":{"underlying":"Common Stock","underlying_shares":2223},"source":{"system":"sec-edgar","filing":"0001127602-21-016827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760221016827/form4.xml","form_type":"4"}},{"id":2734532,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2021-04-30T20:09:22.000Z","date":"2021-04-28","kind":"grant","acquired":true,"shares":703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":703,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":703},"source":{"system":"sec-edgar","filing":"0001127602-21-014772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760221014772/form4.xml","form_type":"4"}},{"id":2734531,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-30T20:09:22.000Z","date":"2021-04-28","kind":"grant","acquired":true,"shares":4081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":4081,"derivative":{"exercise_price":178.68,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":4081},"source":{"system":"sec-edgar","filing":"0001127602-21-014772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760221014772/form4.xml","form_type":"4"}},{"id":381254,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2021-01-29T22:46:18.000Z","date":"2021-01-28","kind":"exercise","acquired":false,"shares":632,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the restricted stock units vested on January 28, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the restricted stock units vested on January 28, 2021."}],"balance_after":1936,"derivative":{"underlying":"Common Stock","underlying_shares":632},"source":{"system":"sec-edgar","filing":"0001127602-21-003029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760221003029/form4.xml","form_type":"4"}},{"id":381253,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-01-29T22:46:18.000Z","date":"2021-01-28","kind":"exercise","acquired":true,"shares":632,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."}],"balance_after":632,"source":{"system":"sec-edgar","filing":"0001127602-21-003029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760221003029/form4.xml","form_type":"4"}},{"id":2973169,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:44:35.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":86083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":86083,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":86083},"source":{"system":"sec-edgar","filing":"0001209191-20-059514","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000120919120059514/doc4.xml","form_type":"4"}},{"id":391049,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2020-05-07T23:39:52.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":7886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on each three-month anniversary measured from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting."}],"balance_after":7886,"derivative":{"exercise_price":77.47,"expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":7886},"source":{"system":"sec-edgar","filing":"0001127602-20-015831","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760220015831/form4.xml","form_type":"4"}},{"id":391048,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2020-05-07T23:39:52.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":1936,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting."}],"balance_after":2568,"derivative":{"underlying":"Common Stock","underlying_shares":1936},"source":{"system":"sec-edgar","filing":"0001127602-20-015831","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760220015831/form4.xml","form_type":"4"}},{"id":3165492,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-01T22:21:25.000Z","date":"2020-04-29","kind":"grant","acquired":true,"shares":18270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":18270,"derivative":{"exercise_price":46.37,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":18270},"source":{"system":"sec-edgar","filing":"0001127602-20-015097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760220015097/form4.xml","form_type":"4"}},{"id":3165491,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-01T22:21:25.000Z","date":"2020-04-29","kind":"grant","acquired":true,"shares":17195,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will be fully vested and exercisable on April 29, 2021."}],"balance_after":17195,"derivative":{"exercise_price":46.37,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":17195},"source":{"system":"sec-edgar","filing":"0001127602-20-015097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760220015097/form4.xml","form_type":"4"}},{"id":396485,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2020-01-30T21:29:01.000Z","date":"2020-01-28","kind":"grant","acquired":true,"shares":632,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the restricted stock units will vest on January 28, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the restricted stock units will vest on January 28, 2021."}],"balance_after":632,"derivative":{"underlying":"Common Stock","underlying_shares":632},"source":{"system":"sec-edgar","filing":"0001127602-20-002759","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760220002759/form4.xml","form_type":"4"}},{"id":396484,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2020-01-30T21:29:01.000Z","date":"2020-01-28","kind":"grant","acquired":true,"shares":3837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on each three-month anniversary measured from January 28, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable on January 28, 2021."}],"balance_after":3837,"derivative":{"exercise_price":64.36,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":3837},"source":{"system":"sec-edgar","filing":"0001127602-20-002759","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760220002759/form4.xml","form_type":"4"}}]}